NEOTHYLLINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOTHYLLINE is an injectable small-molecule drug approved in 1953 by Teva with an unknown mechanism of action and pharmacologic class. The drug's therapeutic indications are not documented in available data. Patient population and clinical use case cannot be determined without additional information.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting limited team growth and focus on transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching status make NEOTHYLLINE a poor career growth opportunity. Roles available are primarily focused on compliance, legal transition, and maintaining existing market share during product decline.
Brand ManagerField Sales Representative
Worked on NEOTHYLLINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.